Appointment of Yves Decadt as Member of Poxel's Board of Directors
Businesswireยท2025-10-31 17:52
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors. Following the governance changes implemented on July 31, this appointment further streng. ...